- Home
- TECX vs CELC Comparison
TECX vs CELC Comparison
Compare TECX & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TECX
- CELC
- Stock Information
- Founded
- TECX 2019
- CELC 2011
- Country
- TECX United States
- CELC United States
- Employees
- TECX N/A
- CELC N/A
- Industry
- TECX
- CELC Medical Specialities
- Sector
- TECX
- CELC Health Care
- Exchange
- TECX Nasdaq
- CELC Nasdaq
- Market Cap
- TECX 602.3M
- CELC 594.7M
- IPO Year
- TECX 2018
- CELC 2017
- Fundamental
- Price
- TECX $45.33
- CELC $15.73
- Analyst Decision
- TECX Strong Buy
- CELC Strong Buy
- Analyst Count
- TECX 4
- CELC 6
- Target Price
- TECX $60.00
- CELC $29.17
- AVG Volume (30 Days)
- TECX 117.9K
- CELC 146.9K
- Earning Date
- TECX 11-24-2024
- CELC 11-14-2024
- Dividend Yield
- TECX N/A
- CELC N/A
- EPS Growth
- TECX N/A
- CELC N/A
- EPS
- TECX N/A
- CELC N/A
- Revenue
- TECX N/A
- CELC N/A
- Revenue This Year
- TECX N/A
- CELC N/A
- Revenue Next Year
- TECX N/A
- CELC N/A
- P/E Ratio
- TECX N/A
- CELC N/A
- Revenue Growth
- TECX N/A
- CELC N/A
- 52 Week Low
- TECX $1.40
- CELC $10.26
- 52 Week High
- TECX $46.91
- CELC $22.19
- Technical
- Relative Strength Index (RSI)
- TECX 83.02
- CELC 52.15
- Support Level
- TECX $40.00
- CELC $14.58
- Resistance Level
- TECX $41.60
- CELC $16.26
- Average True Range (ATR)
- TECX 2.55
- CELC 0.72
- MACD
- TECX 0.24
- CELC -0.00
- Stochastic Oscillator
- TECX 87.58
- CELC 58.58
About TECX Tectonic Therapeutic Inc. Common Stock
Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease.
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are highly differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.